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RESUMEN
La secreción pancreática exocrina es el resultado final de la acción simultánea de múltiples mensajeros extracelulares
sobre las células acinares y ductulares. El proceso global está mediado por un grupo de mensajeros intracelulares
como cAMP, IP3, IP4 o diacilglicerol.
Hormonas como histamina e insulina pueden participar también como agentes reguladores moduladores de la
secreción pancreática. Se ha demostrado que la histamina ejerce un efecto secretagogo moderado a través  de la
modulación de la respuesta secretora inducida por los secretagogos clásicos. La insulina puede potenciar acusadamente
la respuesta secretora a acetilcolina y colecistoquinina. Además, otros péptidos liberados de los islotes de Langerhans
como glucagon, somatostatina y polipéptido pancreático, pueden atenuar las respuestas secretoras inducidas por
colecistoquinina y acetilcolina.
Los factores de crecimiento participan en el control del crecimiento, replicación y diferenciación celular. También
están implicados en la secreción pancreática exocrina. Numerosos estudios han demostrado que los factores de
crecimiento están asociados a la activación de la proteína G. Así, EGF puede estimular o inhibir la adenilato
ciclasa por activación de las proteínas G de tipo G
s 
o Gi.
Se ha mostrado una relación entre EGF y los niveles de colecistoquinina, postulándose un modo dual de acción
del EGF sobre los acinos pancreáticos.
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ABSTRACT
The exocrine pancreatic secretion is the final result of multiple extracellular messengers acting simultaneously on
acinar and ductular cells. The overall process is  mediated by a number at intracellular messengers including cyclic
cAMP, IP3, IP4 or diacylglycerol.
Hormones such as histamine and insuline can also participate as regulatory agents in the modulation of pancreatic
secretion. Histamine has been shown to exert a mild secretagogue-like effect through modulation of the secretory
responses evoked by classical secretagogues. Insuline can markedly potentiate the secretory responses to acetylcholine
and cholecystokinin In addition, other peptides released from the islets of Langerhans, i.e. glucagon, somatostatin and
pancreatic polypeptide can attenuate the secretory responses induced by cholecystokinin and acetylcholine.
Growth factors participate in the control of cell growth, replication and differentiation. They are also involved in the
exocrine pancreatic secretion. Numerous studies have demonstrated that growth factors are coupled to activation of
G proteins. Thus, EGF can stimulate or inhibit adenyl cyclase by activating G
s 
or Gi type G proteins
It has been shown a relationship between EGF and cholecystokinin levels. Moreovera a dual mode of action for
EGFon pancreatic acini has been postulated
KEY WORDS: Growth factors, exocrine pancreas, protein G, EGF, pancreatic secretion.
INTRODUCTION
Growth factors are single chain-polypeptides
that participate in the regulation of cell growth,
replication and differentiation. Their presence in
the systemic circulation allows them to act as
regulators of cell metabolism. They may also act
locally as autocrine or paracrine regulators of
cell function (Canalis et al. 1992). Their interaction
with cognate receptors determines the ability of
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cells to proceed through the cell cycle from non-
proliferating and presynthesis stages into DNA
synthesis phase (Reddy, 1994).
Generally, the interaction of a growth factor
with its receptor leads to the activation of
membrane associated phospholipase C (PLC) that
results in the formation of diacylglycerol (DAG)
and inositol 1,4,5-trisphosphate (IP3) from
phosphatidyl-inositol 4,5-bisphosphate (PIP2)
(Reddy, 1994; Wolfman and Macara,1987). These
events lead to the activation of protein kinases
and calcium mobilization in the cell, resulting in
the activation of many enzyme systems (Sibley
et al.(1988). Also, calcium-induced elevation of
calmodulin levels temporally coincides with the
progression of cells from presynthesis stages to
DNA synthesis phase (Chafouleas et al. 1984).
Mitogen-activated protein (MAP) kinases are also
stimulated by growth factors (Reddy,1994; Saltiel
et al.1993).
It is well known that epidermal (EGF), insulin-
like (IGF-I) and basic fibroblast (bFGF) growth
factors play a decisive role in cell proliferation
and differentiation (Ponyssegur et al. 1992;
Carpenter and Cohen, 1979; Iwashita and
Kobayashi, 1992; Mossner et al. 1985), but the
physiological responses of the pancreatic exocrine
cells to several growth factors remain controversial.
STIMULUS-SECRETION COUPLING IN THE EXOCRINE PANCREAS
Pancreatic acinar cells synthesize and secrete
a variety of digestive enzymes as well as a Na+-
Cl--rich pancreatic juice. Secretion is activated
physiologycally by the gut hormones
cholecystokinin (CCK) and secretin (SEC) and
by the neurotrasmitters acetylcholine (ACh),
noradrenaline (NA) and vasoactive intestinal
peptide (VIP). Other peptides such as bombesin,
substance P, and peptide histidine isoleucine (PHI)
can also act as secretagogues, although their
physiological relevance is less clear. In addition,
regulatory agents that may modulate secretion
include insulin, histamine,somatostatin and growth
factors (Williams and Hootman, 1986).
Stimulation of parasympathetic and
sympathetic nerves results in the release of ACh
and NA respectively, which in turn activate their
respective receptors on pancreatic acinar cells.
Arrival of acidic chyme in the duodenum cau-
ses the release of CCK and SEC from APUD
(amine precursor uptake decarboxilation) cells
into the circulation. These hormones are then
transported to the pancreas where they regulate
pancreatic juice secretion. The exocrine pancreatic
secretion is the final result of multiple extracellular
messengers acting simultaneously on acinar and
ductular cells. It is initiated by binding of
secretagogues to specific receptors on the plas-
ma membrane of the cells. Some of these stimuli
( i.e. : SEC, VIP, NA) evoke their cellular response
through the activation of the plasma membrane-
bound adenylate cyclase resulting in the production
of the second messenger adenosine 3',5'-cyclic
monophosphate (cAMP) (Jensen and Gardner,
1981. The action of CCK on the exocrine pancreas
is similar to ACh and it involves the hydrolysis
of membrane-bound PIP2  which leads to the
formation of such intracellular messengers as IP3
, IP4  and DAG (Putney,1988; Berridge and Irvine,
1989). Both IP3 and IP4 act to mobilize  Ca2+.
IP3 stimulates the release of Ca2+ from the
endoplasmic reticulum and the depletion of this
Ca2+ store enhances Ca2+ influx into pancreatic
acinar cell. The elevated intracellular calcium
[Ca2+]i in turn activates the Ca2+-activated protein
calmodulin and Ca2+-and calmodulin-activated
protein kinases. On the other hand, DAG stimulates
the phospholipid and Ca2+ -dependent enzyme
protein kinase C (PKC). Both PKC and Ca2+-
activated kinases calmodulin phosphorylate
zymogen granules membrane proteins resulting
in swelling of the granules, migration, docking
and fusion with the luminar membrane, exocytosis
and subsequently secretion of digestive enzymes
(Putney,1988; Berridge and Irvine, 1989;
Nishizuka, 1988; Schulz,1989).
REGULATORY AGENTS THAT MAY MODULATE PANCREATIC SECRETION
Histamine is a local hormone present in
pancreas and released in high concentration in
pancreatic juice (Lorenz, 1968) and it has shown
a moderate secretagogue effect on the exocrine
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pancreas in several species including dog, rabbit
and guinea-pig (Liebow and Franklin, 1982;
Iwatsuki et al. ,1981; Pariente et al. ,1989; Pa-
riente et al., 1990; Pariente et al. ,1991), among
others. The secretory effect is mediated via H1
receptors (Pariente et al., 1991). In addition
histamine modulates the secretory responses to
classical secretagogues (Pariente et al., 1991).
To the moment the mechanism of action of
histamine is not totally understood. Although we
have recently shown that at least in part the
response to histamine takes place directly in the
acinar cells (manuscript in preparation) the
possibility exists that histamine also acts in the
pancreatic vasculature and/or in intrapancreatic
neurones. Although histamine can evoke a small
mobilization of calcium (Pariente et al., 1991)
recent data from our laboratory shows that
histamine also interacts with the cAMP signalling
pathway (submitted for publication).
Together, the actual available information
clearly indicate that histamine plays a role as a
local hormone cooperating in the exocrine
pancreatic secretion and modulating the response
to the main secretagogues.
The physiological roles of the islet hormones
in the control of exocrine pancreatic secretion is
less understood. In numerous instances researchers
have reported either a stimulatory effect or an
inhibitory response or none depending on whether
it is an in vivo or an in vitro preparation and
more so the species of animal (Holst, 1985; Chey,
1985; Williams and Goldfine, 1985).
Insulin receptors are located on acinar cells
and the islet hormone alone has little or no effect
on pancreatic enzyme secretion but it can markedly
potentiate the secretory responses to ACh and
CCK-8 (Kanno and  Saito, 1976; Korc et al.
1978; Saito et al.1980; Saito et al. 1980, Sankaran
et al. ,1981; Singh, 1985).
The potentiatory effect of insulin on ACh-
evoked enzyme secretion is believed to be
associated with cyclic AMP metabolism
(Singh,1985; Singh, 1983) and granular regulatory
protein phosphorylation (Williams, 1986; Hootman
and Williams,1987). However, the cellular
mechanism via which insulin acts to enhance the
secretory effect of CCK-8 is not fully understood.
In addition to insulin, the Islet of Langerhans
can also release such peptides as glucagon,
somatostatin and pancreatic polypeptide which
can attenuate the secretory responses evoked by
CCK and ACh in vivo (Chey, 1985). The effect
of these peptides alone or when combined with
either ACh or CCK-8 in isolated pancreatic acini
and acinar cells is less understood (Williams and
Goldfine, 1985).
Several studies have demonstrated the presence
of either one type or another neuropeptide including
atrial natriuretic factor, leucine enkephalin,
pancreastatin and neuropeptide Y in the pancreas
of different animal species and they can all evoke
differential effects on total protein output and
enzyme secretion depending on their concentrations
(Holst, 1985; Juma, 1995; Adeghate, 1996).
EFFECTS OF GROWTH FACTORS IN
THE EXOCRINE PANCREAS
EGF is a 53-amino acid polypeptide that binds
to a single chain 170-kDa receptor with
cytoplasmic protein tyrosine kinase domain. This
receptor type is present on pancreatic acinar cells
(Chabot et al., 1987). EGF and the EGF receptor
agonist transforming growth factor-alfa are
produced among others in pancreatic acinar as
well as in duct cells (Korc et al. 1992). Activation
of the EGF receptor leads to phosphorylation of
several tyrosine residues of the EGF receptor via
an autophosphorylation mechanism (Carpenter and
Cohen, 1990). It is thought that tyrosine
phosphorylation of several substrates including
phospholipase C-gamma, phosphatidyl-inositol 3-
kinase, and Ras-guanosine triphosphatase activating
protein plays a crucial role in the initiation of
signal transduction by the EGF receptor (for a
review see Ullrich and Schlessinger, 1990).
Nevertheless, superphysiological concentrations
of EGF produce only small Ca2+ transient increases
[Ca2+]i and exert statistically insignificant
stimulatory effects on both IP3 levels and amylase
release in rat pancreatic acini (Chandrasekar and
Korc, 1991). Although high concentrations of
EGF stimulate CCK-induced amylase release, at
low concentrations it inhibits CCK-induced
increase in both IP3-production and [Ca2+]i.
Probably, EGF has a dual mode of action in
pancreatic acini resulting in: (a) stimulation of
phosphoinositide-specific, PLC-mediated celular
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responses at high concentrations by a G protein-
insensitive mechanism and (b) inhibition of PLC
at low concentrations, which might involve
activation of inhibitory G proteins (Profrock et
al.1991; Stryjek-Kaminska et al., 1993; Stryjek-
Kaminska et al., 1994; Stryjek-Kaminska et al.,
1995; Stryjek-Kaminska et al., 1995).
Whereas receptors with a seven-transmembrane-
spanning alfa-helical structure are known to interact
with heterotrimeric GTP-binding regulatory
proteins (G proteins), the role of G proteins in
growth factor receptors signaling is less understood.
Some reports indicate that growth factor receptors,
that lack the seven-transmembrane alfa-helical
structure, are also coupled to activation of G
proteins. In rat pancreatic acini the EGF receptor
interacts with GS as well as with Gi-like G proteins
(Profrock, 1991; Profrock et al., 1991), indicating
that EGF may either stimulate or inhibit adenylyl
cyclase by activating G
s
- or Gi-type G proteins,
respectively. Data showing that EGF stimulates
cAMP accumulation and amylase release in
pancreatic acini via a pertussis toxin (PTX)-
insensitive mechanism indicate that EGF recep-
tor-induced activation of GS proteins causes
stimulation of basal adenyl cyclase activity
(Stryjek-Kaminska  et al. 1995), although the
same study demonstrates that EGF inhibits VIP-
and forskolin-induced cAMP production and
amylase secretion and that this inhibitory effect
of EGF is abolished by PTX pretreatment of
the acini. Because PTX catalyzes ADP
ribosylation of alpha-subunits of Gi proteins,
which leads to functional inactivation of the
alpha subunit of Gi proteins (Gilman, 1987), it
is conceivable that EGF inhibits VIP- and
forskolin-induced cAMP production by activating
Gi-like G proteins.
Initiation of cellular responses by bFGF begins
with binding to its specific tyrosine kinase re-
ceptor (Coughlin et al. 1988) and subsequent
activation of PLC-gamma (Kuo, 1990), the enzyme
that induces the hydrolysis of phosphatidyl-inositol
4,5-bisphosphate (PIP2). bFGF also inhibits EGF
binding in acinar cell (Korc, 1983). The ability
of bFGF to initiate PIP2 hydrolysis suggests that
this pathway may play a pivotal role in mediating
the actions of bFGF in some cell types. In fact,
bFGF  is a calcium mobilizing agonist in the
pancreatic acinar cell that induces a rapid and
dose-dependent increase in IP3  and [Ca2+]i levels
of rat pancreatic acini and also stimulates amylase
release in a dose-dependent manner. On a molar
basis bFGF is more potent than carbachol as
stimulant of amylase release and the ability of
bFGF to raise [Ca2+]i levels is  abolished by
pretreatment of acini with carbachol, a G-protein
-coupled cholinergic agonist, as a result of the
depletion of IP3-sensitive calcium pools
(Chandrasekar and  Korc, 1991).
IGF-1 is an insulin-like growth factor that
binds to specific receptors in isolated pancreatic
acini (Williams et al. 1984). It has no effect on
either IP3 production, calcium transient increase,
or amylase release (Chandrasekar and  Korc, 1991).
In the rat pancreatic acinar tumoral cell line AR
42J cells, IGF-I stimulated growth and increased
amylase content. However, its effects were much
weaker than insulin, suggesting that the IGF-I
evoked response at least may be mediated through
the insulin receptor (Mossner et al., 1985).
Recently, it has been shown that EGF,IGF-I
and bFGF share the activation of a common
pathway in cellular signal transduction that
involves phospholipase D (PLD). Although the
mechanism of phosphatidic acid production, as a
consequence of PLD activation, seems different
for the three growth factors, there is no doubt of
a specific PLD activation as unequivocally
demonstrated by the production of
phosphatidylethanol (Rydzewska et al., 1995;
Rydzewska et al.,1995; Rivard et al. 1995).
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